Article
Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Cancer chemotherapy and pharmacology - 1 Oct 2020
Ariyasu Ryo, Yanagitani Noriko, Tadokoro Kenichi, Yamaguchi Toshikazu, Uchibori Ken, Kitazono Satoru, Fujita Naoya, Katayama Ryohei, Nishio Makoto
Abstract excerpt
PURPOSE: Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer with BIM deletion polymorphism may have a limited response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, some results of previous reports are discordant. It is necessary to evaluate the relationship between BIM polymorphism and the efficacy of EGFR-TKIs. METHODS: We retrospectively analyzed patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
